The Role of Type 2 Diabetes Mellitus–Related Risk Factors and Drugs in Hepatocellular Carcinoma
Yuhua Mai,Liheng Meng,Ganlu Deng,Yingfen Qin
DOI: https://doi.org/10.2147/jhc.s441672
2024-01-20
Journal of Hepatocellular Carcinoma
Abstract:Yuhua Mai, 1, 2 Liheng Meng, 1 Ganlu Deng, 2, 3 Yingfen Qin 1 1 Department of Endocrinology, The First Affiliated Hospital of GuangXi Medical University, Nanning, Guangxi, 530021, People's Republic of China; 2 Guangxi Key Laboratory of Enhanced Recovery after Surgery for Gastrointestinal Cancer (Guangxi Medical University), Ministry of Education, Nanning, Guangxi, 530021, People's Republic of China; 3 Department of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, People's Republic of China Correspondence: Yingfen Qin, Department of Endocrinology, The First Affiliated Hospital of GuangXi Medical University, Nanning, 530021, Guangxi, People's Republic of China, Tel/Fax +86-13607862619, Email Ganlu Deng, Department of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, People's Republic of China, Tel/Fax +86-15676132389, Email With changes in modern lifestyles, type 2 diabetes mellitus (T2DM) has become a global epidemic metabolic disease, and hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. T2DM is a complex metabolic disorder and has been considered an independent risk factor for HCC. Growing evidence supports that T2DM-related risk factors facilitate hepatocarcinogenesis via abundant mechanisms. With the wide implementation of microbiomics, transcriptomics, and immunotherapy, the understanding of the complex mechanisms of intestinal flora and immune cell subsets have advanced tremendously in T2DM-related HCC, uncovering new findings in T2DM-related HCC patients. In addition, reports have indicated the different effects of anti-DM drugs on the progression of HCC. In this review, we summarize the effects of major T2DM-related risk factors (including hyperglycemia, hyperinsulinemia, insulin, chronic inflammation, obesity, nonalcoholic fatty liver disease, gut microbiota and immunomodulation), and anti-DM drugs on the carcinogensis and progression of HCC, as well as their potential molecular mechanisms. In addition, other factors (miRNAs, genes, and lifestyle) related to T2DM-related HCC are discussed. We propose a refined concept by which T2DM-related risk factors and anti-DM drugs contribute to HCC and discuss research directions prompted by such evidence worth pursuing in the coming years. Finally, we put forward novel therapeutic approaches to improve the prognosis of T2DM-related HCC, including exploiting novel diagnostic biomarkers, combination therapy with immunocheckpoint inhibitors, and enhancement of the standardized management of T2DM patients. Keywords: type 2 diabetes mellitus, hepatocellular carcinoma, NAFLD, gut microbiota, inflammatory, immunotherapy China has a high incidence of liver cancer, and liver cancer mortality ranks third among all cancer-related deaths. 1 Hepatocellular carcinoma (HCC) accounts for 75%–85% of liver cancer cases, and approximately 45% of HCC deaths occur in China. 2 Chronic inflammations caused by viral hepatitis, especially hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, contribute majorly to HCC via changing the hepatic immune system, while the etiology cause by alcohol abuse shows an increasing trend. Despite great efforts put into medical technologies, the survival likelihood of HCC patients is still gloomy due to the lack of early diagnosis and drug resistance. 3 Therefore, there is an urgent need to develop novel treatment strategies to improve the prognosis of HCC patients. Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by insulin-secretion deficiency or insensitive insulation of target cells, resulting in insulin resistance (IR) and liver damage. The increasing incidence of T2DM has become a global public health concern. 4 Increasing evidence suggests that T2DM is an important risk factor for HCC; 5–7 however, studies on how DM contributes to the occurrence and progression of HCC are scarce. It is necessary to explore the relationship between T2DM and HCC, particularly the role of T2DM in HCC. This paper discusses the mechanisms that T2DM contribute to the progression of HCC that are currently known, mainly including the effects of hyperglycemia, hyperinsulinemia, IR, chronic inflammation, nonalcoholic fatty liver disease (NAFLD), obesity, and altered gut microbiota. Meanwhile, the effects of hypoglycemic drugs on HCC will be analyzed, with the aim of revealing the connection between T2DM and HCC and the potential mechanisms. This review broadens the understanding of HCC risk factors and contributes toward the development of better treatment strategies for HCC by utilizing T2DM related factors. HCC is the sixth–most common human ma -Abstract Truncated-
oncology